We are at a pivotal time for treatment innovations in hematological malignancies – Anas Younes
We are at a pivotal time for treatment innovations in hematological malignancies, and our data at ASCO23, EHA2023 and 17ICML reflect our ambition to leverage the potential of next generation modalities with the goal of redefining the treatment landscape for people with blood cancers.
By harnessing disease understanding and exploring different combination strategies, we aim to drive deeper, more durable responses and work towards the possibility of cure.
I am truly grateful to be a part of the growing team at AstraZeneca that have dedicated their work to unravel some of our biggest challenges in the hematology treatment landscape. Congratulations to all on the successful congress season so far. I look forward to sharing more of our data throughout the year.